MRNAModerna

Health care · Biotechnology · Nasdaq

Moderna is a pioneer and leader in the field of mRNA medicine. 10-K, Item 1

Employees: 4,700
Headquarters: Cambridge, MA
CEO: Stephane Bancel
Next results: around Jan 11, 2027

The numbers MRNA said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 3 range targets with a reported result: 1 came in above the last range given, 2 within it, 0 below it.

Target	What the company said	Reported	Result
Capital expenditures Fiscal 2026	Given $200.00M to $300.00M release 2026-02-13 Kept $200.00M to $300.00M release 2026-05-01 Kept $200.00M to $300.00M release 2026-07-31	–	Not reported yet
The company's words Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. release 2026-02-13 Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. release 2026-05-01 Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. release 2026-07-31
Revenue Fiscal 2026	Given $900.00M release 2026-02-13 Raised $1.80B release 2026-05-01 Lowered $1.70B release 2026-07-31 Kept $1.70B release 2026-11-06	–	Not reported yet
The company's words Cost of Sales: Cost of sales for 2026 is expected to be approximately $0.9 billion. release 2026-02-13 Cost of Sales: Cost of sales for 2026 is now expected to be approximately $1.8 billion, including the $0.9 billion non-recurring litigation settlement charge. release 2026-05-01 Cost of Sales: Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge. release 2026-07-31 Cost of Sales: Cost of sales for 2026 is expected to be approximately $1.7 billion, including the previously announced $0.9 billion non-recurring litigation settlement charge. release 2026-11-06
Revenue Fiscal 2025 (ended 2025-12-31)	Given $1.20B release 2025-02-14 Kept $1.20B release 2025-05-01 Raised $1.50B to $2.20B release 2025-08-01 Lowered $1.60B to $2.00B release 2025-11-06	$1.94B 10-K filed 2026-02-20	Within the range
The company's words Cost of Sales: Cost of sales for 2025 is expected to be approximately $1.2 billion. release 2025-02-14 Cost of Sales: Cost of sales for 2025 is expected to be approximately $1.2 billion. release 2025-05-01 Revenue: The Company updated its 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end of the range. release 2025-08-01 Narrows 2025 projected revenue range to $1.6 - $2.0 billion release 2025-11-06
Capital expenditures Fiscal 2024 (ended 2024-12-31)	Given $900.00M release 2024-02-22 Kept $900.00M release 2024-05-02 Kept $900.00M release 2024-08-01	$1.05B 10-K filed 2025-02-21	Above the range
The company's words Capital Expenditures: The Company expects capital expenditures for 2024 of approximately $0.9 billion. release 2024-02-22 Capital Expenditures: Capital expenditures for 2024 are expected to be approximately $0.9 billion. release 2024-05-02 Capital Expenditures: Capital expenditures for 2024 are expected to be approximately $0.9 billion. release 2024-08-01
Revenue Fiscal 2024 (ended 2024-12-31)	Given $4.00B release 2024-01-08 Kept $4.00B release 2024-02-22 Kept $4.00B release 2024-05-02 Lowered $3.00B to $3.50B release 2024-08-01 Kept $3.00B to $3.50B release 2024-11-07	$3.24B 10-K filed 2025-02-21	Within the range
The company's words Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment release 2024-01-08 Reaffirms 2024 expected product sales of approximately $4 billion release 2024-02-22 Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion release 2024-05-02 Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion release 2024-08-01 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion release 2024-11-07

1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)

Capital expenditures, Fiscal 2025 (ended 2025-12-31): said $300.00M, reported $192.00M. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (16 releases since 2023-11-02), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on MRNA in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/MRNA/export.csv") into a cell.